DBV

DBV Technologies is the only company in the world whose products are designed to epicutaneously deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food allergies or allergy diagnosis. DBV Technologies is listed on the EuroNext [DBV] and is a French company focused on the development of innovative products for the diagnosis and treatment of food allergies.

SofinnovaCapital

The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

SofinnovaMD Start

The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

SofinnovaCrossover

The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

SofinnovaIndustrial Biotech

Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

SofinnovaTelethon

The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

SofinnovaDigital Medicine

The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.

SofinnovaBiovelocita

The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.

Join our mailing list

Keep up to date with our latest news.

Required
Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.